Innovative products that serve unmet medical needs/significantly advance patient care. Have chemical structures that have never been approved before.

Adlyxin,  Anthim,  Axumin,  Briviact,  Cinqair, Defitelio, Epclusa, Eucrisa, Exondys 51, Lartruvo, Netspot, Nuplazid, Ocaliva, Rubraca, Spinraza, Taltz, Tecentriq, Venclexta, Xiidra, Zepatier, Zinbryta, Zinplava


  • Impact: Public health, First-in-class,  Rare diseases
  • Innovation: Breakthrough, Fast Track, Pirority Review, Accelerated Approva
  • Predictability: Met PDUFA goal date
  • Access: First cycle approval, First approval in US


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account.
Log Out / 
Change )

Google photo

You are commenting using your Google account.
Log Out / 
Change )

Twitter picture

You are commenting using your Twitter account.
Log Out / 
Change )

Facebook photo

You are commenting using your Facebook account.
Log Out / 
Change )

Connecting to %s